Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02205762 · ClinicalTrials.gov registry record · Phase 2
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
A Phase 2 study of Langerhans Cell Histiocytosis, sponsored by North American Consortium for Histiocytosis.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 1,400
- Enrollment target
- 20
- Study locations
NCT02205762: Recruiting Phase 2 study of Langerhans Cell Histiocytosis, sponsored by North American Consortium for Histiocytosis.
NCT02205762 is a Phase 2 study of Langerhans Cell Histiocytosis that is actively recruiting participants, run by North American Consortium for Histiocytosis. The registered enrollment target is 1,400 participants, above the 964-participant average among 8 other Langerhans Cell Histiocytosis trials with a reported enrollment target (45% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02205762, a Phase 2 study of Langerhans Cell Histiocytosis, is actively recruiting participants, sponsored by North American Consortium for Histiocytosis.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,400 participants
- Enrollment target
- 20
- Study locations
Study Summary
The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age \< 18 years).
Primary Outcome
Stratum I, II, VI
Conditions Studied
Interventions
- DRUG Prednisone
- DRUG Methotrexate
- DRUG Vinblastine
- DRUG mercaptopurine
- DRUG INDOMETHACIN
Study Locations (20)
California
- Children's Hospital of Los Angeles - Los Angeles
- Valley Children's Healthcare - Madera
- UCSF Benioff Children's Hospital of Oakland - Oakland
- Children's Hospital of Orange County - Orange
- UCSF Helen Diller Family Cancer Center - San Francisco
Kentucky
- University of Kentucky A.B.Chandler Medical Center - Lexington
- University of Louisville, Norton Children's Hospital - Louisville
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Alabama
- Children's of Alabama - Birmingham
Arizona
- Phoenix Children's Hospital - Phoenix
Arkansas
- Arkansas Children's Hospital - Little Rock
Connecticut
- Connecticut Children's Medical Center - Hartford
District of Columbia
- Children's National Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,400 participants |
| Start Date | 2016-11-02 |
| Est. Completion | 2026-07 |
| Phase | Phase 2 |
What NCT02205762 shows while recruiting
NCT02205762 is an interventional study that assigns participants to a tested intervention. Its 1,400 participants enrollment target places it among the larger protocols in the corpus, above the 964-participant average among 8 other Langerhans Cell Histiocytosis trials with a reported enrollment target (45% higher).
The record links to 1 condition, with Langerhans Cell Histiocytosis appearing as the primary indexed condition, and to 5 interventions - of which Prednisone is the first listed.
NCT02205762 names 20 study sites across 14 states, led by California, Kentucky, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02205762 about?
NCT02205762 is a clinical study titled "LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis". The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age \< 18 years).
What is the current status of trial NCT02205762?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,400 participants. The study started on 2016-11-02. Estimated completion is 2026-07.
What conditions does trial NCT02205762 study?
This clinical trial studies the following conditions: Langerhans Cell Histiocytosis.
What interventions are being tested in trial NCT02205762?
The interventions under investigation include: Prednisone (DRUG), Methotrexate (DRUG), Vinblastine (DRUG), mercaptopurine (DRUG), INDOMETHACIN (DRUG).
Who is sponsoring clinical trial NCT02205762?
This trial is sponsored by North American Consortium for Histiocytosis, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02205762 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Langerhans Cell Histiocytosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02205762's enrollment target sits among peer trials
1,400 2nd of 8 the highest of 8 other Langerhans Cell Histiocytosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Langerhans Cell Histiocytosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib
RECRUITING · Phase 2
-
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
RECRUITING · Phase 2
-
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis
COMPLETED · Phase 2
-
Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445222 · 1,400 participants · Phase 3
CAR-T Long Term Follow Up (LTFU) Study
- NCT03145077 · 1,400 participants · NA
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Diagnosing Osteoradionecrosis in Patients With Head and Neck Cancer That Is Primary, Has Come Back, or Has Spread to Other Places in the Body
- NCT04250857 · 1,400 participants
HeartStart FRx Defibrillator Event Registry
- NCT04840797 · 1,400 participants
HeartStart HS1 Defibrillator* Event Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI